<DOC>
	<DOC>NCT02635776</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.</brief_summary>
	<brief_title>Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)</brief_title>
	<detailed_description>This is an international, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of AR101 in a characterized desensitization oral immunotherapy regimen in peanut-allergic individuals.</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Key Age 4 through 55 years Clinical history of allergy to peanuts or peanutcontaining foods Serum immunoglobulin E (IgE) to peanut ≥0.35 kUA/L (kilos of allergenspecific units per liter, determined by UniCAP™* within the past 12 months) and/or a skin prick test (SPT) to peanut ≥3 mm compared to control Experience doselimiting symptoms at or before the 100 mg challenge dose of peanut protein (measured as 200 mg of peanut flour) on Screening DBPCFC conducted in accordance with PRACTALL** guidelines Not be residing at the same address as another subject in this or any peanut OIT study UniCAP™*: a laboratory system for routine diagnostic testing of allergy and tool for basic studies on allergens and antibodies PRACTALL**: PRACTical issues in ALLergology Joint United States/European Union Initiative Key History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension History of severe or lifethreatening episode of anaphylaxis or anaphylactic shock within 60 days of Screening DBPCFC History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema Developing doselimiting symptoms in reaction to the placebo part of the Screening DBPCFC Having the same place of residence as another subject in the study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AR101 (Characterized Peanut Allergen)</keyword>
	<keyword>Characterized Peanut Allergen</keyword>
	<keyword>CPNA (Characterized Peanut Allergen)</keyword>
	<keyword>OIT (oral immunotherapy)</keyword>
	<keyword>Oral Immunotherapy</keyword>
	<keyword>Peanut Allergy</keyword>
	<keyword>Allergy</keyword>
	<keyword>Peanut-Allergic Children</keyword>
	<keyword>Peanut-Allergic Adults</keyword>
	<keyword>Desensitization</keyword>
</DOC>